

Date : 21.07.2024

To, The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 543945	To, The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai- 400051 Scrip Code: NETWEB
---	---

Dear Sir/Madam,

**SUB: INTIMATION OF PUBLICATION OF NEWSPAPER ADVERTISEMENT
PERTAINING TO CONVENING OF 25TH ANNUAL GENERAL MEETING
THROUGH VIDEO CONFERENCING OR OTHER AUDIO-VISUAL MEANS
(OAVM)**

In pursuance to Regulation 30, Regulation 47 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the copies of the newspaper advertisement published, pertaining to convening of 25th Annual General Meeting through Video Conferencing or Other Audio-Visual Means (OAVM).

We request you to take the same on record.

Thanking You,

Yours faithfully
For **Netweb Technologies India Limited**

Lohit Chhabra
Company Secretary & Compliance Officer
M. No. A36610

VIPUL ORGANICS LIMITED

(CIN: L2410MH1972PLC015857)

Registered Office: 102, Andheri Industrial Estate, Off. Veera Desai Road, Andheri (West), Mumbai - 400053
 Corporate Office: B 603-A, Kaledonia, Sahar Road, Off. W.E. Highway, Andheri (East), Mumbai - 400069
 Telephone no. 022-66139999, Fax no. 022-66139977/5 Email ID: info@vipulorganics.com Website: www.vipulorganics.com

Extract of statement of Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024 (Rs. in Lakh except EPS)

Sr. No.	Particulars	Standalone			Consolidated		
		Quarter ended 30.06.2024	Year ended 31.03.2024	Quarter ended 30.06.2024	Year ended 30.06.2023	Year ended 31.03.2024	
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Total income from operations (net)	3819.94	3,623.80	15,099.30	3819.94	3,623.80	15,099.30
2	Net Profit/(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	158.67	70.80	463.88	158.21	70.07	463.88
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	158.67	70.80	463.88	158.21	70.07	463.88
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	113.9	51.71	334.44	113.44	51.71	334.44
5	Total Comprehensive Income for the period [(comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	113.69	50.01	333.71	113.23	50.01	333.71
6	Paid up Equity Share Capital (Face value of Rs. 10/- each)	1301.19	1281.19	1301.19	1301.19	1,281.19	1,301.19
7	Reserves (excluding Revaluation Reserves as per Balance Sheet of previous accounting year)	0	0	0	0	0	0
8	Earning per Equity share of Rs. 10/- each						
	(a) Basic	0.88	0.40	2.60	0.87	0.40	2.57
	(b) Diluted	0.88	0.40	2.60	0.87	0.40	2.57

- Notes:
- The above Unaudited Standalone and Consolidated Financial Results for the quarter 30th June, 2024 were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on Friday, 19th July, 2024 and Statutory Auditors of the Company have carried out a "Limited Review" of the same.
 - Based on the "management approach" as defined in Ind AS-108- Operating Segments, the Company operates in one segment i.e. Dyesstuff, Organic Pigments and Organic Intermediates. Hence, disclosure of segment wise information is not applicable.
 - The figures for the quarter ended 31.03.2024 are balancing figures between the audited figures in respect of the full financial year ended on that date and published un-audited year-to-date figures upto 31.12.2023.
 - Previous periods' figures have been regrouped/rearranged wherever considered necessary to confirm to the presentation of the current period. All the figures of financial results have been rounded off to nearest Lakh rupees.

For VIPUL ORGANICS LIMITED

Sd/-

Vipul P. Shah

Managing Director

DIN: 00181636

Place: Mumbai

Date: 19th July, 2024

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as Genlink Pharma Investments Private Limited)

CIN: U74110MH2016PTC280765

Reg Off: 401, 4th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai, 400705, Maharashtra, India.
 Ph: +91 22 6750 7000 Fax: +91 22 6750 7070 Email: genlinkinfo@gmail.com Website: www.genlinkpharma.com

Extract of Standalone Audited Financial Results for the quarter and year ended 31st March, 2024 (INR)

Particulars	Quarter ending 31/03/2024		Corresponding Quarter for the previous year ended 31/03/2023		Year Ended 31st March 2024
	(Audited)	(Audited)	(Audited)	(Audited)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
Total income from operations	1,089,000	1,221,506	4,356,000	4,356,000	4,356,000
Net Profit/(Loss) for the period (before tax and/or Exceptional and/or Extraordinary items)	-2,045,112	267,332	-2,212,946	-2,212,946	-2,212,946
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	-2,045,112	267,332	-2,212,946	-2,212,946	-2,212,946
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	-2,045,112	214,865	-2,290,342	-2,290,342	-2,290,342
Total Comprehensive Income for the period (comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax))	-2,045,112	214,865	-2,290,342	-2,290,342	-2,290,342
Paid Equity Share Capital	100,000	100,000	100,000	100,000	100,000
Reserves (excluding Revaluation Reserve)	2,673,544	5,063,886	2,673,544	2,673,544	2,673,544
Securities premium account	-	-	-	-	-
Net Worth	2,773,544	5,163,886	2,773,544	2,773,544	2,773,544
Paid up debt Capital/Outstanding Debt	21,676,531	24,614,531	21,676,531	21,676,531	21,676,531
Outstanding Redeemable Debentures	250,000,000	250,000,000	250,000,000	250,000,000	250,000,000
Debt Equity Ratio	97.95	53.18	97.95	97.95	97.95
Earnings Per Share (of 10/- each) (for continuing and discontinued operations)					
Basic	(204.51)	21.49	(204.51)	(204.51)	(204.51)
Diluted	(204.51)	21.49	(204.51)	(204.51)	(204.51)
Capital Redemption Reserve	-	-	-	-	-
Debt Service Coverage Ratio	-	-	-	-	-
Interest Service Coverage Ratio	(0.01)	0.00	(0.01)	(0.01)	(0.01)
	(5.95)	1.62	(5.95)	(5.95)	(5.95)

- Notes:
- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange under Regulation 52 of the LODR Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchanges (www.bseindia.com) and the listed entity (https://genlinkpharma.com/investor-relations.html).
 - The above results were approved by the Board of Directors at their meeting held on 19th July, 2024.
 - For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Bombay Stock Exchange and can be accessed on www.bseindia.com and can be accessed on Company's website (https://genlinkpharma.com/investor-relations.html).
 - As there has been no change in accounting policies, hence no impact on net profit/ loss, total comprehensive income or any other relevant financial item(s).

For Genlink Pharma Solutions Private Limited

Sd/-

Anand Shah

Director

DIN: 00597145

Sd/-

Sushel Koul

Managing Director

DIN: 00925887

Date: 19/07/2024

Place: Navi Mumbai

MOTISONS JEWELLERS LIMITED

Motisons Jeweller Ltd.

Registered Office: 270, 271, 272 & 76, Johri Bazar, Jaipur

Corporate Office: SB-110, Motisons Tower, Lalkothi, Tonk Road, Jaipur Tel No: +91-0141-4160000
 Email: compliance@motisons.com | Website: www.motisonsjewellers.com | CIN: L36911RJ2011PLC035122

Extract of Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2024 (Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			
		30-06-2024		31-03-2024	
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from operations	8,907.58	11,699.77	8,676.26	41,717.65
2	Net Profit/(Loss) for the period (before tax, exceptional and extraordinary items)	848.87	1,509.96	735.79	4,483.84
3	Net Profit/(Loss) for the period before tax (after exceptional and extraordinary items)	848.87	1,568.60	735.79	4,454.96
4	Net Profit/(Loss) for the period after tax (after exceptional and extraordinary items)	633.20	1,078.80	547.76	3,223.11
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax))	625.15	1,076.88	548.70	3,220.33
6	Equity Share Capital	9,844.60	9,844.60	6,497.50	9,844.60
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,969.83	7,783.88	22,969.83
8	Earnings per Equity Share (of Face Value Rs. 10 each) (for continuing and discontinued operations) -				
	(1) Basic	0.64	1.10	0.84	4.30
	(2) Diluted	0.64	1.10	0.84	4.30

- Note:
- The above is an extract of the detailed format of Unaudited Financial Results for the quarter ended 30.06.2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). The full format of the financial results for the quarter ended 30th June, 2024 is available on Company's website (www.motisonsjewellers.com) and on Stock Exchange's website viz. www.bseindia.com and www.nseindia.com.
 - The above results were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors of the Company at their respective meetings held on 20th July, 2024. A limited review of the above results has been carried out by the statutory auditors of the Company.

For and on behalf of the Board of Directors

Motisons Jewellers Limited

Sd/-

Sandeep Chhabra

Chairman & Whole-Time Director

DIN: 00120838

Date: 20/07/2024

Place: Jaipur

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

CIN: L24100MH2009PLC194818

Regd. Office: 201 A & B, 2nd Floor, Akruvi Corporate Park, L.B.S. Marg,

Next to GE Gardens, Kanjurmarg (W) Mumbai - 400 078

T: +91-22-6123 3800 F: +91-22-25796982 E: info@rossari.com W: www.rossari.com



making you more competitive

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2024 (Rs. in Million)

Particulars	Quarter ended		
	30 th June, 2024	31 st Mar., 2024	30 th June, 2023
	(Unaudited)	(Audited)	(Unaudited)
Total income from operations	4,896.50	18,305.58	4,106.06
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	469.87	1,776.15	394.57
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	469.87	1,776.15	394.57
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	348.99	1,306.89	292.19
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	349.01	1,306.98	293.04
Equity Share Capital	110.49	110.49	110.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.			
Earnings Per Share (of Rs. 2/- each) (for continuing and discontinued operations) -			
Basic	6.32*	23.67	5.30*
Diluted	6.30*	23.62	5.28*

*Not Annualized

Additional Information on Standalone Financial Results is as follows (Rs. in Million)

Particulars	Quarter ended		
	30 th June, 2024	31 st Mar., 2024	30 th June, 2023
	(Unaudited)	(Audited)	(Unaudited)
(a) Total income from operations	3,007.08	12,029.10	2,583.42
(b) Profit Before Tax	326.72	1,341.34	290.88
(c) Profit After Tax	243.28	996.45	215.57

- Notes:
- The Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 20th July, 2024. A review of the above interim financial results has been carried out by the statutory auditors.
 - The above is an extract of detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchange where shares of the Company are listed i.e. www.bseindia.com and www.nseindia.com and also on the website of the Company i.e. www.rossari.com

For ROSSARI BIOTECH LIMITED

Sd/-

EDWARD MENEZES

Executive Chairman

DIN: 00149205

Place: MUMBAI

Date: 20th July, 2024

KOTAK MAHINDRA BANK LIMITED

CIN - L65110MH1985PLC038137

Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Tel.: +91-22-61660001 Fax: +91 22 6713 2403

Website: www.kotak.com E-mail: KotakBank.Secretarial@kotak.com

FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2024 (₹ in crore)

Particulars	STANDALONE			CONSOLIDATED		
	Quarter ended 30 th June, 2024	Year ended 31 st March, 2024	Quarter ended 30 th June, 2023	Quarter ended 30 th June, 2024	Year ended 31 st March, 2024	Quarter ended 30 th June, 2023
	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)
Total income from operations (net)	15,675.15	56,072.01	13,183.26	25,075.87	94,273.91	20,723.91
Net Profit / (Loss) (before tax, extraordinary items)	8,195.53	18,013.72	4,585.26	9,810.99	23,863.38	5,586.43
Net Profit / (Loss) before tax (after extraordinary items)	8,195.53	18,013.72	4,585.26	9,810.99	23,863.38	5,586.43
Net Profit / (Loss) after tax (before extraordinary items)	6,249.82	13,781.58	3,452.30	7,448.16	18,213.21	4,150.19
Net Profit / (Loss) after tax (after extraordinary items)	6,249.82	13,781.58	3,452.30	7,448.16	18,213.21	4,150.19
Paid up Equity Share Capital	993.98	993.96	993.61	993.98	993.96	993.61
Reserves (excluding Revaluation Reserves and Minority Interest)	95,645.50**	95,645.50**	81,966.67*	128,898.44**	128,898.44**	110,760.81*
Basic Earnings per equity share (before extraordinary items) (of ₹ 5/- each) (not annualised)	31.44	69.15	17.38	37.47	91.45	20.89
Diluted Earnings per equity share (before extraordinary items) (of ₹ 5/- each) (not annualised)	31.44	69.15	17.38	37.47	91.45	20.89
Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-	-	-	-	-	-
Securities Premium Account	25,205.62	25,201.47	25,083.24			
Net worth	106,054.39	96,066.10	86,434.93			
Outstanding debt	29,402.13	28,368.10	20,378.16			
Outstanding redeemable preference shares	NA	NA	NA			
Debt-Equity Ratio	0.28	0.29	0.23			

* As on 31st March 2023** As on 31st March 2024

Note:

- The above is the extract of the detailed format of the Quarterly Financial Results filed with the Stock Exchanges under Regulations 33 and 52 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results is available on the websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and also on website of the Bank (https://www.kotak.com/en/investor-relations/financial-results.html?source=website).

- As Ind AS is not applicable to Banking companies, total Comprehensive Income and other comprehensive income is not applicable.

- Information as required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Methodology for computation of the ratios is as follows:

Debt-Equity ratio	Represents the ratio of Borrowings / Sum of Capital and Reserves and Surplus
Networth	Calculated as per the Master Circular - Exposure Norms issued by the RBI.

- Debtenture Redemption Reserve is not applicable to the Bank.

- During the quarter, The Bank has implemented the Master Direction - Classification, Valuation and Operation of Investment Portfolio of Commercial Banks (Directions), 2023 dated 12th September, 2023 which is applicable to banks from 1st April, 2024. The Group entities other than Bank, continue to follow AS - 13 "Accounting for Investments" and IRDA guidelines, as applicable.

- There has been no change to significant accounting policies during the quarter ended 30th June, 2024 as compared to those followed for the year ended 31st March, 2024 except as disclosed in Note 5.

By Order of the Board of Directors

For Kotak Mahindra Bank Limited

Sd/-

Ashok Vaswani

Managing Director & CEO

Mumbai, 20th July, 2024

NETWEB TECHNOLOGIES INDIA LIMITED